High dose of plasmid IL-15 inhibits immune responses in an influenza non-human primates immunogenicity model.
Interleukin (IL)-15, is a cytokine that is important for the maintenance of long-lasting, high-avidity T cell response to invading pathogens and has, therefore, been used in vaccine and therapeutic platforms as an adjuvant. In addition to pure protein delivery, plasmids encoding the IL-15 gene have been utilized. However, it is critical to determine the appropriate dose to maximize the adjuvanting effects. We immunized rhesus macaques with different doses of IL-15 expressing plasmid in an influenza non-human primate immunogenicity model. We found that co-immunization of rhesus macaques with a Flu DNA-based vaccine and low doses of plasmid encoding macaque IL-15 enhanced the production of IFN-gamma (0.5 mg) and the proliferation of CD4(+) and CD8(+) T cells, as well as T(CM) levels in proliferating CD8(+) T cells (0.25 mg). Whereas, high doses of IL-15 (4 mg) decrease the production of IFN-gamma and the proliferation of CD4(+) and CD8(+) T cells and T(CM) levels in the proliferating CD4(+) and CD8(+) T cells. In addition, the data of hemagglutination inhibition (HI) antibody titer suggest that although not significantly different, there appears to be a slight increase in antibodies at lower doses of IL-15. Importantly, however, the higher doses of IL-15 decrease the antibody levels significantly. This study demonstrates the importance of optimizing DNA-based cytokine adjuvants.
Yin
Jiangmei
J
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 505 SCL, 422 Curie Blvd. Philadelphia, PA 19104, USA.
Dai
Anlan
A
Laddy
Dominick J
DJ
Yan
Jian
J
Arango
Tatiana
T
Khan
Amir S
AS
Lewis
Mark G
MG
Andersen
Hanne
H
Kutzler
Michele A
MA
Draghia-Akli
Ruxandra
R
Weiner
David B
DB
Boyer
Jean D
JD
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D049109:Cell Proliferation; D004305:Dose-Response Relationship, Drug; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007252:Influenza Vaccines / Q000235:genetics / Q000276:immunology*; D007371:Interferon-gamma / Q000378:metabolism; D019409:Interleukin-15 / Q000235:genetics / Q000276:immunology*; D008253:Macaca mulatta; D010957:Plasmids; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology*
D000914:Antibodies, Viral; D007252:Influenza Vaccines; D019409:Interleukin-15; D019444:Vaccines, DNA; D007371:Interferon-gamma
Nat Rev Genet. 2008 Oct;9(10):776-88
18781156
Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3392-7
12626740
Immunity. 2001 Feb;14(2):105-10
11239443
Blood. 2003 Feb 1;101(3):1024-9
12393488
Science. 2000 Apr 28;288(5466):675-8
10784451
J Virol. 2005 Apr;79(8):4877-85
15795273
J Immunol. 2008 Jun 15;180(12):7969-79
18523260
J Clin Invest. 2006 Jun;116(6):1514-24
16691294
Expert Rev Vaccines. 2008 Sep;7(7):1085-101
18767956
Immunol Res. 2008;42(1-3):219-32
19066740
Vaccine. 2008 Jan 17;26(3):440-8
18082294
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11445-50
11016962
J Immunol. 2005 Jul 1;175(1):112-23
15972637
Virus Res. 2004 Jul;103(1-2):91-5
15163495
Vaccine. 2004 Sep 3;22(25-26):3510-21
15308379
Vaccine. 2007 Jun 21;25(26):4967-82
17335943
J Exp Med. 2002 Jun 17;195(12):1541-8
12070282
Immunity. 1998 May;8(5):591-9
9620680
J Virol. 2002 Jan;76(1):243-50
11739689
J Immunol. 1997 Jun 15;158(12):5978-87
9190952
J Immunol. 2002 Jan 1;168(1):29-43
11751943
Blood. 2004 Feb 1;103(3):988-94
14512307
J Immunol. 2008 Jan 1;180(1):350-60
18097036
Microbes Infect. 2003 Mar;5(3):227-31
12681412
Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18648-53
18000037
Hamostaseologie. 2007 Feb;27(1):22-31
17279273
AIDS. 2008 Sep 12;22(14):1739-48
18753858
PLoS One. 2008 Jun 25;3(6):e2517
18575608